Waters Corporation WAT ← Back to all reports

Waters Corporation

WAT · Healthcare
B ★★★ Hold
Nov 6, 2026 · Score 68 · Type A — Value-style analysis Used for established, cash-generative companies — weighs earnings power, valuation against the company's own history and peers, and margin of safety. Full methodology →
Current PriceThe market price around the time this report was written — not a live quote. The market has moved since; check a current price before acting.Methodology → $453.08
Buy ZoneThe large figure is the midpoint of the suggested buy range shown in parentheses. $410.00 ($400.00–$420.00)
Price TargetOur estimated fair value. For richly valued stocks it can sit below the current price — see Methodology.Methodology → $472.50
Expected Return
  • Target relative to the Current Price ((Target − Current) ÷ Current). Since that price is from the report date, your actual return will differ.
  • A negative Expected Return means the Price Target is below the report-date Current Price. This can occur even with a Buy or Strong Buy recommendation because recommendations follow a fixed mapping from the overall investment score, which combines business assessment, valuation and risk. This is a limitation of our score-based framework: a favorable recommendation does not always imply an attractive entry price. Consider the Price Target, Buy Zone and valuation analysis together.
Methodology →
+4.3%

Type A - Waters Corporation (WAT) 20261106 Stock Analysis

📅 Waters Key Upcoming Events

🏢 Step 1: Waters Company Overview & Business Model

Q1-A1. What is Waters?

Q1-A2. How Does Waters Make Money?

Q1-A3. Waters’s Revenue Segments & Core Income Sources

Q1-A4. Who Are Waters’s Competitors?

Q1-A5. Waters Key Events: Past 12 Months

Q1-A6. Step 1 Key Takeaways

🏰 Step 2: Waters’s Economic Moat, Growth & Capital Allocation

Q2-A1. Does Waters Have a Durable Economic Moat?

Q2-A2. Is Waters’s Growth Sustainable?

Q2-A3. How Does Waters Allocate Capital & Return Cash?

Q2-A4. Step 2 Key Takeaways

💰 Step 3: Is Waters Profitable? Financial Health Analysis

Q3-A2. How Profitable Is Waters? (Margins & ROIC)

Q3-A3. What Drives Waters’s Returns? (ROIC Breakdown)

Q3-A4. Are Waters’s Earnings High Quality?

Q3-A5. Is Waters’s Balance Sheet Healthy? (Debt & Leverage)

Q3-A6. Step 3 Key Takeaways

🔎 Step 4: Waters Forensic Accounting & Dilution Review

Q4-A1. Does Waters Have Accounting Red Flags?

Q4-A2. Is Waters Overspending? (Capex & Capital Cycle)

Q4-A3. How Sound Is Waters’s Cash Flow?

Q4-A4. Is Waters Diluting Shareholders?

Q4-A5. Data Integrity Check

Q4-A6. Step 4 Key Takeaways

👔 Step 5: Waters Management & Shareholder Alignment

Q5-A1. Can You Trust Waters’s Management? (Guidance Track Record)

Q5-A2. What Are Waters Insiders Doing?

Q5-A3. Is Waters’s Management Aligned With Shareholders?

Q5-A4. Step 5 Key Takeaways

⛵ Step 6: Waters Market Flow & Sentiment

Q6-A1. Analyst Consensus vs Waters Guidance

Q6-A2. What Is Waters’s Short Interest?

Q6-A3. Step 6 Key Takeaways

🚀 Step 7: Waters Catalysts & Price Triggers

Q7-A1. What Could Move Waters Stock? (Top 3 Catalysts)

Q7-A2. Waters’s Earnings Revision Trend

Q7-A3. Step 7 Key Takeaways

⚖️ Step 8: Is Waters Fairly Valued? Valuation Analysis

Q8-A1. Waters’s Key Valuation Multiples

Q8-A2. Waters vs Peers: Valuation Comparison

Q8-A3. Is Waters Cheap or Expensive vs Its History?

Q8-A4. What Growth Is Priced Into Waters? (Reverse DCF)

Q8-A4-1. What Growth Hurdle Does the Market Demand From Waters? (Reverse DCF Alternative)

Q8-A5. Waters’s Hidden Asset & Stake Valuation

Q8-A6. Final Valuation Adjustment

Q8-A7. Valuation Adjustment Score Calculation

💀 Step 9: What Are the Risks of Waters? Fatal Risks & Pre-Mortem

Q9-A1. What Are the Biggest Risks to Waters?

Q9-A2. How Sensitive Is Waters to the Economy?

Q9-A3. Waters Pre-Mortem: What Could Go Wrong?

Q9-A4. Risk Adjustment Score

🎯 Step 10: Waters Final Verdict: Score & Rating

Q10-A1. Investment Score & Rating

Q10-A2. Should You Buy Waters? (Recommendation)

Q10-A3. Investment Thesis in One Line

Q10-A4. Waters’s Price Trend & Key Drivers

Q10-A5. Action Plan

🕵️‍♂️ Deep Dive Analysis

Q1: Is Waters’ Acquisition-Driven Leverage and Cash-Flow Weakness Its Biggest Investment Risk?

Q2: Can Waters’ 28.65x Forward P/E Be Justified by Its Expanded Diagnostics and Life Sciences Portfolio?

Q3: Can Waters Sustain High-Single-Digit Organic Growth After the Initial Recovery in Laboratory Demand?

Q4: Will Waters’ BD Combination Improve Long-Term Returns on Invested Capital?

Q5: How Much Does Waters Depend on Pharmaceutical and Biotechnology Capital Spending?

Q6: Can Waters Turn Its Growing Diagnostics Business Into a Durable Competitive Advantage?

Q7: Could Waters’ MOBILion Acquisition Strengthen Its Position in Proteomics and Complex Molecular Analysis?

Q8: Will Waters’ Elevated Debt Restrict Future Acquisitions and Shareholder Returns?

Q9: Can Waters’ Adjusted EPS Growth Be Trusted While GAAP Earnings Remain Depressed?

Q10: What Would Most Clearly Justify a Bullish Reassessment of Waters During FY2027?

Rating History

Rating History shows the Rating assigned on each report date. Only the latest report is available to read. Scores are omitted from the timeline because reports from different periods may follow different rating scales.

  1. 2026-07 B
  2. 2026-08 B
  3. 2026-11 B